Fred Y Aoki

Summary

Affiliation: University of Manitoba
Country: Canada

Publications

  1. ncbi Oseltamivir: a clinical and pharmacological perspective
    K E Doucette
    Section of Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada
    Expert Opin Pharmacother 2:1671-83. 2001
  2. ncbi The continuing evolution of antiviral therapy for recurrent genital herpes: 1-day patient-initiated treatment with famciclovir
    Fred Y Aoki
    University of Manitoba, Winnipeg, Manitoba, Canada
    Herpes 14:62-5. 2007
  3. ncbi Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial
    Fred Y Aoki
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba
    Clin Infect Dis 42:8-13. 2006
  4. ncbi Early administration of oral oseltamivir increases the benefits of influenza treatment
    F Y Aoki
    University of Manitoba, Room 510 730 William Avenue, Winnipeg, Canada
    J Antimicrob Chemother 51:123-9. 2003
  5. ncbi Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients
    Herman Lam
    Department of Internal Medicine, University of Manitoba, Winnipeg, Canada
    Ther Drug Monit 33:699-704. 2011
  6. ncbi Hospitalizations and deaths due to respiratory illnesses during influenza seasons: a comparison of community residents, senior housing residents, and nursing home residents
    Verena H Menec
    Department of Community Health Sciences and Manitoba Centre for Health Policy, The University of Manitoba, Winnipeg, Canada
    J Gerontol A Biol Sci Med Sci 57:M629-35. 2002
  7. ncbi The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality
    Verena H Menec
    University of Manitoba, Winnipeg, MB, Department of Community Health Sciences
    Can J Public Health 94:59-63. 2003
  8. ncbi Influenza virus susceptibility and resistance to oseltamivir
    Fred Y Aoki
    Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Antivir Ther 12:603-16. 2007
  9. ncbi Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective
    Donald C Vinh
    University of Manitoba, Infectious Diseases and Medical Microbiology, Section of Infectious Diseases, Department of Medicine, Department of Medical Microbiology, Winnipeg, Manitoba, R3E 0W3, Canada
    Expert Opin Pharmacother 7:2271-86. 2006
  10. ncbi Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine
    Daniel S Sitar
    Section of Clinical PharmacologyDepartment of Internal Medicine, Faculty of Medicine, University of Manitoba, A220-753 McDermot Avenue, Winnipeg, Manitoba R3E 0T6
    J Clin Pharmacol 48:995-8. 2008

Detail Information

Publications15

  1. ncbi Oseltamivir: a clinical and pharmacological perspective
    K E Doucette
    Section of Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada
    Expert Opin Pharmacother 2:1671-83. 2001
    ....
  2. ncbi The continuing evolution of antiviral therapy for recurrent genital herpes: 1-day patient-initiated treatment with famciclovir
    Fred Y Aoki
    University of Manitoba, Winnipeg, Manitoba, Canada
    Herpes 14:62-5. 2007
    ..This paper reviews the progressive convergence of these concepts to an efficacious, well-tolerated, 1-day, patient-initiated regimen for treating episodes of recurrent genital herpes...
  3. ncbi Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial
    Fred Y Aoki
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba
    Clin Infect Dis 42:8-13. 2006
    ..This study was conducted to assess the efficacy and safety of a patient-initiated, single-day regimen of famciclovir therapy, compared with placebo, in immunocompetent adult patients with recurrent genital herpes...
  4. ncbi Early administration of oral oseltamivir increases the benefits of influenza treatment
    F Y Aoki
    University of Manitoba, Room 510 730 William Avenue, Winnipeg, Canada
    J Antimicrob Chemother 51:123-9. 2003
    ..Thus, early presentation, diagnosis and treatment of patients with influenza maximized the benefits of oseltamivir therapy...
  5. ncbi Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients
    Herman Lam
    Department of Internal Medicine, University of Manitoba, Winnipeg, Canada
    Ther Drug Monit 33:699-704. 2011
    ..This study was conducted to determine whether adverse symptoms and acute drug interactions occur during their coadministration...
  6. ncbi Hospitalizations and deaths due to respiratory illnesses during influenza seasons: a comparison of community residents, senior housing residents, and nursing home residents
    Verena H Menec
    Department of Community Health Sciences and Manitoba Centre for Health Policy, The University of Manitoba, Winnipeg, Canada
    J Gerontol A Biol Sci Med Sci 57:M629-35. 2002
    ....
  7. ncbi The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality
    Verena H Menec
    University of Manitoba, Winnipeg, MB, Department of Community Health Sciences
    Can J Public Health 94:59-63. 2003
    ..Their impact on mortality was also examined...
  8. ncbi Influenza virus susceptibility and resistance to oseltamivir
    Fred Y Aoki
    Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Antivir Ther 12:603-16. 2007
    ..However, continued vigilance, especially of emerging avian H5N1 strains, combined with careful, systematic laboratory-based monitoring, is essential...
  9. ncbi Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective
    Donald C Vinh
    University of Manitoba, Infectious Diseases and Medical Microbiology, Section of Infectious Diseases, Department of Medicine, Department of Medical Microbiology, Winnipeg, Manitoba, R3E 0W3, Canada
    Expert Opin Pharmacother 7:2271-86. 2006
    ..These results have been demonstrated in various patient populations, including immunocompetent patients and those infected with HIV. Famciclovir is well tolerated, with an adverse events profile similar to placebo...
  10. ncbi Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine
    Daniel S Sitar
    Section of Clinical PharmacologyDepartment of Internal Medicine, Faculty of Medicine, University of Manitoba, A220-753 McDermot Avenue, Winnipeg, Manitoba R3E 0T6
    J Clin Pharmacol 48:995-8. 2008
  11. ncbi Glycoprotein-D-adjuvant vaccine to prevent genital herpes
    Lawrence R Stanberry
    Department of Pediatrics and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston 77555 0351, USA
    N Engl J Med 347:1652-61. 2002
    ..An effective prophylactic vaccine would help control the spread of genital herpes...
  12. ncbi Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding
    Anna Wald
    Department of Medicine, School of Medicine and School of Public Health and Community Medicine, University of Washington, Seattle, Washington 98122, USA
    Sex Transm Dis 33:529-33. 2006
    ..However, few comparative studies between the 2 antivirals have been performed...
  13. ncbi Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial
    Stephen L Sacks
    Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Clin Infect Dis 41:1097-104. 2005
    ..These results support the use of treatment with famciclovir at a dosage of 125 mg for 5 days as an effective, well-tolerated treatment for episodes of recurrent genital herpes...
  14. ncbi Short-course therapy for recurrent genital herpes and herpes labialis
    Spotswood Spruance
    Division of Infectious Diseases, University of Utah School of Medicine, Room 4B319, 30 North 1900 East, Salt Lake City, UT 84132-2405, USA
    J Fam Pract 56:30-6. 2007
  15. ncbi Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine
    David I Bernstein
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA
    Clin Infect Dis 40:1271-81. 2005
    ....